



PATIENT PRESENTING CLINICAL SIGNS

Dugg North History: Grade 3/6 murmur. Assess prior to anesthesia.
-Current medications: Clavamox, Carprofen

SPECIES ECHOCARDIOGRAM FINDINGS

Canine 2D, m-mode, color flow and doppler imaging is available. The mitral valve is diffusely thickened with prolapse into the left atrial lumen. There is severe eccentric mitral regurgitation present. The MR velocity is normal. There is severe left atrial enlargement. There is moderate left ventricular dilation. Left ventricular systolic function is hyperdynamic. Mild right atrial and ventricular dilation (subjective). Mild thickening of the tricuspid valve with mild TR. Normal velocity. There is normal systolic flow velocity across the aortic valve. The aortic valve appears trileaflet with normal mobility. The main pulmonary artery is normal in diameter. The pulmonic valve is normal in appearance. No pericardial/pleural effusion or cardiac masses are seen.

BREED

Dachshund Mix

SEX CARDIAC CHART

Male Neutered

AGE

13 years

WEIGHT

22lbs

INTERPRETED BY

Maggie Machen
Lamy, DVM, DACVIM
(Cardiology)

IMAGING PERFORMED BY

Rebekah Jakum, CVT
ARDMS/RVT

HOSPITAL NAME

Pocono Peak VC

REFERRING VET

Dr. Norris

INVOICE

29643

DATE


3/16/23

CANINE CARDIAC PARAMETERS	MR VMAX (m/s)	TR VMAX (m/s)	LA/AO (Boon method)	LA/AO (Heart Base; Swe)	FS (%)	EF (%)	EPSS (cm)
NORMAL PARAMETER	4.5-5.5	<2.7	1.3	<1.6	28-40	40-100	<0.6
PATIENT	5.4	2.7	NM	2.2	42	73	0.18
CANINE CARDIAC PARAMETER RS	HR (BP M)	AV VMAX (m/s)	PV MAX (m/s)	BODY WEIGHT (kg)	LA 2D short axis Base view (cm)	LVIDd Avg; 2D and m-mode short axis (cm)	LVIDs Avg; 2D and m-mode short axis (cm)
NORMAL PARAMETER	50-100	0.7-1.7	0.7-1.6	BELOW	BELOW	BELOW	BELOW
PATIENT	111	1.7	0.8	10.0	2.8	4.9	2.6
*Normal chamber parameters expressed as a mean value				3	1.27	2.46	1.36
BODY WEIGHT DEPENDENT PARAMETERS				5	1.40	2.74	1.60
*Note: All measurements based upon multi-modal images and methods. An average value is reported.				10	1.50	3.27	2.06
				15	1.83	3.71	2.43
				20	2.02	4.14	2.80
				25	2.18	4.48	3.10
				30	2.33	4.83	3.39
				35	2.48	5.17	3.69
				40	2.62	5.48	3.96
				50	2.88	6.07	4.46

INTERPRETATION OF THE FINDINGS & FURTHER RECOMMENDATIONS

Chronic degenerative valve disease causing severe mitral and mild tricuspid regurgitation. The LA is significantly dilated indicating a high risk for clinical signs going forward. No additional concurrent issues such as systolic dysfunction are documented.

With this degree of left heart changes, the risk for spontaneous congestive heart failure is elevated and cardiac supportive medications are indicated as below. A weak diuretic (spironolactone) is included given high risk for decompensation in the future even with no reported symptoms.



PATIENT

Dugg North

Assessment of progression in the future will help predict long term outcome, however prognosis is guarded at this stage (late B2). Unfortunately the patient will always be at risk for recurrent CHF, development of arrhythmias/LA tear, syncope and/or sudden death in the future.

SPECIES

Canine

Close monitoring for development of associated clinical signs (development of a cough, labored breathing, exercise intolerance or worsening collapse episodes) is recommended. Monitoring of sleeping breathing rates is recommended as the best way to screen for CHF at home.

BREED

Dachshund Mix

Elective anesthesia is not advised, as there is high risk for complication. If necessary, cardiac protective drug choices (opioid/benzodiazepine premedication, propofol or alfaxalone induction, iso or sevoflurane gas) are recommended. Pre-oxygenate for 5-10 minutes prior to induction and recover in O2 cage. Monitor for arrhythmias, hypotension, and hypoxia both intra and post-operatively and intervene as necessary. Moderate IV fluid restriction is recommended to avoid fluid overload. Avoid heart rate stimulating drugs such as atropine unless clinically indicated.

SEX

Male Neutered

Omega fatty acid supplementation and mild salt restriction may also be of some long term benefit.

PLAN

AGE

13 years

A screening BP is recommended. Administer Pimobendan 0.3mg/kg PO q12h. Institute ACE-I (benazepril or enalapril) 0.5mg/kg PO q12h. Institute spironolactone 1-2mg/kg PO q12h.

Monitor renal values in 1-2 weeks, then every 3-4 months lifelong to ensure tolerance of medications.

WEIGHT


22lbs

A recheck echocardiogram is recommended in 4-6 months to screen for progression, sooner if clinical signs arise.

INTERPRETED BY

Maggie Machen
Lamy, DVM, DACVIM
(Cardiology)

IMAGES



IMAGING PERFORMED BY

Rebekah Jakum, CVT
ARDMS/RVT

HOSPITAL NAME

Pocono Peak VC

The information and recommendations provided are based on the images presented by the referring veterinarian. No evaluation can be communicated regarding pathology that was not visible in the image/video clips provided.

REFERRING VET

Dr. Norris

Thank you for this referral. If the clinical or image interpretation does not parallel your findings or if I can be of any further assistance please contact me.

INVOICE

29643

Maggie Machen Lamy, DVM
Diplomate of the American College of Veterinary Internal Medicine (Cardiology)
info@sonopath.com

DATE

3/16/23